中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

94 records (took 0.024 seconds)

    METHOD FOR IDENTIFYING ATTENUATED VARICELLA VIRUS OKA STRAIN OR A STRAIN DERIVED THEREFROM
    44.
    发明授权
    METHOD FOR IDENTIFYING ATTENUATED VARICELLA VIRUS OKA STRAIN OR A STRAIN DERIVED THEREFROM 失效
    一种鉴定减毒水痘病毒由干OKA或WHICH基质干

    公开(公告)号：EP0839911B1

    公开(公告)日：2004-07-28

    申请号：EP97922068.8

    申请日：1997-05-15

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： MORI, Chisato ,  TAKAHARA, Rie ,  OSAME, Juichiro ,  GOMI, Yasuyuki ,  FUKE, Isao

    IPC: C12N15/38 ,  C12Q1/70 ,  C12N7/00 ,  C07K14/04 ,  A61K39/25

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2710/16722 ,  C12Q1/701

    Abstract: A novel and dependable method for identifying an attenuated chickenpox virus Oka strain or a strain originating therein and acceptable as an attenuated chickenpox vaccine virus which comprises distinguishing the above-mentioned Oka strain from a specimen by examining whether the chickenpox virus genomic DNA of the Oka strain agrees with that of the specimen in all of the eight requirements as will be defined hereinbelow or disagrees therewith in at least one of these eight requirements so as to identify the Oka strain: the size of the restriction enzyme Hpa I fragment K; the size of the restriction enzyme Eco RI fragment P; the size determination of the Gene 14 R2-487 region; the PCR-SSCP determination of this region; the size of the restriction enzyme AccIII fragment in the R2-1764 region: the occurrence of the restriction enzyme Pst I site in this region; the homology of the amino acid sequence encoded by the R2-487 region; and the homology of the amino acid sequence encoded by the entire ORF of VZV Gene 14. Also provided are a virus strain substantially identical to the attenuated chickenpox virus Oka strain or a strain originating therein and acceptable as an attenuated chickenpox vaccine virus which has been identified by the above-mentioned method; an attenuated chickenpox vaccine with the use of the virus strain as the active ingredient; and a gp V antigen encoded by Gene 14 which is useful as a diagnostic agent.

    ROTAVIRUS ANTIGENS, VACCINES AND DIAGNOSTIC DRUGS FOR INFECTION WITH ROTAVIRUS, AND PROCESSES FOR PRODUCING THE SAME
    45.
    发明公开
    ROTAVIRUS ANTIGENS, VACCINES AND DIAGNOSTIC DRUGS FOR INFECTION WITH ROTAVIRUS, AND PROCESSES FOR PRODUCING THE SAME 失效
    轮状病毒抗原，疫苗和药物抗感染轮状病毒，及其制备方法

    公开(公告)号：EP0878541A1

    公开(公告)日：1998-11-18

    申请号：EP97944176.3

    申请日：1997-10-20

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： NAKAGOMI, Osamu,19-8, Yanagida-aza-sakaida ,  NAKAGOMI, Toyoko ,  MURAKAMI, Shigeki; ,  IMAKAWA, Tadashi;

    IPC: C12N7/00 ,  A61K39/15 ,  G01N33/569

    CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5252 ,  C12N2720/12334

    Abstract: The present invention provides a method for producing a rotavirus antigen of which the mass culture is difficult, comprising cloning a cell highly permitting the proliferation of rotavirus from a cell culture; preparing a cloned cell adapted-rotavirus strain by passaging a rotavirus in the resulting cloned cell strain and adapting the rotavirus to the cloned cell strain; culturing as a seed virus the adapted rotavirus strain or a reassortant prepared by using the adapted rotavirus strain as a parent strain; and isolating and purifying the rotavirus antigen from the culture medium of the seed virus; and additionally provides an rotavirus antigen, a vaccine against rotavirus infections, and a diagnostic agent of the diseases, as produced by using the antigen. These antigen, vaccine and diagnostic agent can make great contributions to individual fields of the fundamental research works and clinical application, relating to rotavirus infections.

    Abstract translation: 本发明提供了用于产生轮状病毒抗原哪大量培养是困难的，包括克隆的细胞高度允许从细胞培养轮状病毒增殖的方法; 制备克隆细胞angepasst轮状病毒应变时效通过传递所得到的克隆细胞株轮状病毒和使轮状病毒适应克隆的细胞株; 培养作为种子病毒的angepasst的轮状病毒毒株或者通过使用angepasst的轮状病毒毒株作为亲本株制备的重配; 和分离和纯化从种子病毒的培养基中的轮状病毒抗原; 并且另外提供关于轮状病毒抗原，抗轮状病毒感染的疫苗，以及疾病的诊断剂，通过使用该抗原产生的。 这些抗原，疫苗和诊断试剂可以对基础研究工作和临床应用的各个领域的巨大贡献，与轮状病毒感染。

    METHOD FOR IDENTIFYING ATTENUATED CHICKENPOX VIRUS OKA STRAIN OR STRAIN ORIGINATING THEREIN AND ACCEPTABLE AS ATTENUATED CHICKENPOX VACCINE VIRUS
    46.
    发明公开
    METHOD FOR IDENTIFYING ATTENUATED CHICKENPOX VIRUS OKA STRAIN OR STRAIN ORIGINATING THEREIN AND ACCEPTABLE AS ATTENUATED CHICKENPOX VACCINE VIRUS 失效
    一种鉴定减毒水痘病毒由干OKA或WHICH基质干

    公开(公告)号：EP0839911A1

    公开(公告)日：1998-05-06

    申请号：EP97922068.8

    申请日：1997-05-15

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： MORI, Chisato ,  TAKAHARA, Rie ,  OSAME, Juichiro ,  GOMI, Yasuyuki ,  FUKE, Isao

    IPC: C12N15/38 ,  C12Q1/70 ,  C12N7/00 ,  C07K14/04 ,  A61K39/25

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N2710/16722 ,  C12Q1/701

    Abstract: Disclosed is a method for exact identification of the attenuated varicella virus Oka strain or a strain derived therefrom capable of functioning as an attenuated varicella live vaccine virus, which comprises analyzing the difference in the genomic DNA and fragments thereof between the Oka strain and a sample varicella strain, and determining whether or not a sample strain satisfies all of the following eight characteristics: the sizes of the Hpa I-K fragment and the Eco RI-P fragment; the size of R2-487 region of Gene14 and the analysis by PCR-SSCP; the sizes of the restriction fragments obtained by digesting the R2-1764 fragment with Acc III; the absence or presence of a Pst I cleavage site; the homology of the amino acid sequences coded by R2-487 coding region; and the homology of the amino acid sequences coded by the coding region of VZV Gene14 . Also disclosed are an isolated virus strain which is substantially the same virus strain as identified by the above method; an attenuated varicella virus live vaccine comprising the same virus strain as identified by the above method; and an attenuated varicella virus Oka strain antigen.

    Abstract translation: 公开了一种用于减毒水痘病毒Oka株的准确识别或从能够作为减毒水痘活疫苗病毒，其包含Oka株和样品水痘之间分析所述基因组DNA及其片段的区别它们的作用的衍生有一个应变的方法 应变，和确定性采矿是否样品应变SATIS外资企业所有的以下八个特征：对HPA-K片段和的EcoRI-P片段的大小; Gene14并通过PCR-SSCP分析R2-487的区域的尺寸; 通过用消化的的AccIII片段R2-1764获得的限制性片段的大小; 不存在或一个裂解位点的PstI的存在; 通过R2-487编码区编码的氨基酸序列的同源性; 和氨基酸序列的同源性由VZV Gene14的编码区编码。 所以圆盘游离缺失是在分离的病毒株的所有其基本上作为鉴定通过上述方法相同的病毒株; 的减毒水痘病毒活疫苗，其包含鉴定通过上述方法相同的病毒株; 和减毒水痘病毒Oka株抗原。

    Stabilized varicella live vaccine
    48.
    发明公开
    Stabilized varicella live vaccine 失效
    稳定的水痘活疫苗

    公开(公告)号：EP0568726A3

    公开(公告)日：1994-08-31

    申请号：EP92113567.9

    申请日：1992-08-08

    Applicant: The Research Foundation for Microbial Diseases of Osaka University

    Inventor： Koyama, Kuniaki ,  Osame, Juichiro

    IPC: A61K39/25 ,  A61K39/295

    CPC classification number: A61K39/25 ,  A61K39/0015 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/70 ,  C12N2710/16734 ,  Y02A50/39

    Abstract: Disclosed is a stabilized live vaccine containing a varicella virus and a stabilizer, wherein the vaccine is substantially free of Ca²⁺ ions and Mg²⁺ ions. This stabilized live vaccine is extremely excellent in storage stability and heat resistance. Also disclosed is an improved stabilizer for a live varicella vaccine, comprising at least one member selected from gelatin and hydrolyzed gelatin, each being substantially free of Ca²⁺ ions and Mg²⁺ ions. The stabilizer can advantageously be used to stabilize a live vaccine containing a varicella virus. The substantial freedom of Ca²⁺ ions and Mg²⁺ ions can be attained by masking Ca²⁺ ions and Mg²⁺ ions present in a live vaccine containing a varicella virus and a stabilizer, with a chelating reagent, or by using as a stabilizer gelatin and/or a gelatin derivative after being purified to remove Ca²⁺ ions and/or Mg²⁺ ions contained therein.

    Abstract translation: 公开了含有水痘病毒和稳定剂的稳定化活疫苗，其中疫苗基本上不含Ca 2+离子和Mg 2+离子。 这种稳定化的活疫苗在储存稳定性和耐热性方面非常优异。 还公开了用于活水痘疫苗的改进的稳定剂，其包含至少一种选自明胶和水解明胶的成分，每种成分基本上不含Ca 2+离子和Mg 2+离子。 稳定剂可以有利地用于稳定含有水痘病毒的活疫苗。 通过用螯合剂掩蔽存在于含有水痘病毒和稳定剂的活疫苗中的Ca 2+离子和Mg 2+离子，或通过用作稳定剂明胶和/或稳定剂可以获得Ca 2+离子和Mg 2+离子的实质自由度， 或在纯化后除去其中所含的Ca 2+离子和/或Mg 2+离子的明胶衍生物。

    HIV Gag-env fusion antigen
    49.
    发明公开
    HIV Gag-env fusion antigen 失效
    Gag-Env融合抗原艾滋病毒。

    公开(公告)号：EP0572737A2

    公开(公告)日：1993-12-08

    申请号：EP92311006.8

    申请日：1992-12-02

    Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

    Inventor： Saito, Atsushi ,  Sinagawa, Hideo ,  Nakata, Atsuo

    IPC: C12N15/49 ,  C12N15/62 ,  A61K39/21 ,  C07K13/00 ,  G01N33/53

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/16322 ,  Y10S435/974

    Abstract: Disclosed is a substantially pure HIV antigen comprising a Gag-Env fusion protein consisting of a Gag peptide fused at its C-terminus to an Env peptide, wherein the Gag peptide comprises a contiguous sequence of at least ten amino acids of the amino acid sequence represented by Gag (308-437) and the Env peptide comprises a contiguous sequence of at least a part of the amino acid sequence represented by Env (512-699), the part containing at least one epitope which is reactive to an HIV antibody. The gag - env fusion DNA corresponding to the HIV antigen of the present invention allows the production of the desired high antigenicity HIV antigen in high yield. Therefore, the HIV antigen of the present invention can be advantageously used as an active component for a diagnostic reagent, a vaccine, an antibody preparation and a therapeutic reagent for AIDS. Also disclosed is a substantially pure HIV antigen comprising a Gag protein coded for by the entire gag gene.

    Abstract translation: 公开了一种基本上纯的HIV抗原，其包含由其C-末端融合到Env肽的Gag肽组成的Gag-Env融合蛋白，其中所述Gag肽包含表示的氨基酸序列的至少十个氨基酸的连续序列 通过Gag（308-437），并且Env肽包含由Env（512-699）表示的至少一部分氨基酸序列的连续序列，该部分含有至少一个对HIV抗体具有反应性的表位。 对应于本发明的HIV抗原的gag-env融合DNA允许以高产率产生所需的高抗原性HIV抗原。 因此，本发明的HIV抗原可以有利地用作诊断试剂，疫苗，抗体制剂和用于AIDS的治疗试剂的活性成分。 还公开了包含由整个gag基因编码的Gag蛋白质的基本上纯的HIV抗原。

Patent Agency Ranking